Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer

References

• Buzdar A, Chlebowski R, Cuzick J, et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 2006;22:1575–85
   PubMed Web of Science ®Google Scholar
• Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633–43
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–2
   PubMed Web of Science ®Google Scholar
• Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analysis. Cancer 2003;98:1802–10
   PubMed Web of Science ®Google Scholar
• Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359:2131–9
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–57
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;50:1081–92
   Google Scholar
• Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455–62
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793–802
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–71
   PubMed Web of Science ®Google Scholar
• Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002;17:172–8
   PubMed Web of Science ®Google Scholar
• Ismail AA, Pye SR, Cockerill WC, et al. Incidence of limb fracture across Europe: Results from the European Prospective Osteoporosis Study. Osteoporos Int 2002;13:565–71
   PubMed Web of Science ®Google Scholar
• Howell A. Effect of anastrozole on bone mineral density: 2-year results of the ‘Arimidex’ (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial. Breast Cancer Res Treat 2003;82:S27 (Abstract 129)
   Google Scholar
• Lønning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23: 5126–37
   Google Scholar
• Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–35
   PubMed Web of Science ®Google Scholar
• Coleman R, et al. Effect of anastrozole on bone mineral density: 5-year results form ‘Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial’. J Clin Oncol 2006;24:18S (Abstract 511)
   Google Scholar
• Love RR, Barden HS, Mazess R, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585–8
   PubMed Web of Science ®Google Scholar
• Neele SJ, Evertz R, De Valk-De Roo G, et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30: 599–603
   Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Can Inst 1998;90:1371–88
   PubMed Web of Science ®Google Scholar
• Bell R, Sambrook P, Chen Z, Lewis J. Relative risk for fractures in postmenopausal women, postmenopausal breast cancer survivors and postmenopausal women managed with adjuvant hormonal therapy. Eur J Cancer 2006;4:95 (Abstract 175)
   Google Scholar
• Chen Z, Maricic M, Bassford TL, et al. Fracture risk among breast cancer survivors: Results from the Women’s Health Initiative Observational Study. Arch Intern Med 2005;165:552–8
   PubMed Web of Science ®Google Scholar
• Cooley H, Jones G. A population-based study of fracture incidence in southern Tasmania: Lifetime fracture risk and evidence for geographic variations within the same country. Osteoporosis Int 2001;12:124–30
   PubMed Web of Science ®Google Scholar
• Greep NC, Giuliano AE, Hansen NM, et al. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 2003;114:653–9
   PubMed Web of Science ®Google Scholar
• Firipis M. Managing osteoporosis in women with breast cancer. In: Clinical Updates in Breast Cancer 2006;1:8–10
   Google Scholar
• Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829–36
   PubMed Web of Science ®Google Scholar
• Davidson N, Neven P, Llombart A, et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in post-menopausal women receiving letrozole as adjuvant therapy for early breast cancer. Breast 2005;14\(Suppl 1):S44 (Abstract P105)
   Google Scholar
• Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006;33:13–17
   PubMed Web of Science ®Google Scholar
• Osteoporosis Australia. Medical Only, an insert in Osteoblast, Summer 2004
   Google Scholar
• Hillner BE, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–57
   PubMed Web of Science ®Google Scholar
• Australian Clinical Trials Registry. Available at: www.actr.org.au [Last accessed 13 February 2007
   Google Scholar